8-K/A: Neuronetics Completes Acquisition of Greenbrook TMS Inc., Bolstering Mental Health Treatment Network

Neuronetics finalizes its acquisition of Greenbrook TMS Inc., expanding its footprint in the mental health services sector.

Summary

• Neuronetics, Inc. has completed its acquisition of Greenbrook TMS Inc. effective December 9, 2024.
• The acquisition was executed through an arrangement agreement dated August 11, 2024, under the Business Corporations Act (Ontario).
• Greenbrook's shareholders received 0.01021 shares of Neuronetics common stock for each Greenbrook share.
• Madryn Asset Management converted Greenbrook's credit agreement into 2,056,453,835 Greenbrook Shares and interim funding into an additional 252,999,770 Greenbrook Shares before the exchange.
• The combined company will operate as Neuronetics, Inc., with shares trading on the NASDAQ Global Market under the ticker STIM.
• The fair value of the total consideration was approximately $34.7 million.
• The preliminary purchase price allocation is based on estimates, assumptions, valuations and other analysis which have not yet been finalized.

Sentiment

Score: 5

Explanation: The document is neutral. While the acquisition itself is a positive strategic move, the financial details reveal ongoing losses and the need for restructuring, balancing the overall sentiment.

Positives

• The acquisition expands Neuronetics' presence in the mental health treatment market.
• The combined company is expected to benefit from synergies and operational efficiencies.
• The transaction has been approved by both companies' shareholders and the Ontario Superior Court of Justice.
• The combined company will continue to operate as Neuronetics, Inc.

Negatives

• Greenbrook has experienced losses since inception and has negative cash flow from operating activities of $36,809,738 for the nine months ended September 30, 2024.
• The preliminary purchase price allocation is based on estimates, assumptions, valuations and other analysis which have not yet been finalized.
• The pro forma financial statements do not reflect the costs of any integration activities nor the synergies and benefits that may result from realization of any operational efficiencies expected to result from the Acquisition of Greenbrook.

Risks

• The final acquisition accounting is dependent on information that has not yet been finalized, and differences between preliminary estimates and final accounting could have a material impact.
• The pro forma financial statements do not reflect the costs of any integration activities nor the synergies and benefits that may result from realization of any operational efficiencies expected to result from the Acquisition of Greenbrook.
• Greenbrook has historically not been able to meet its forecast.
• The Company will require additional financing in order to fund its operating and investing activities in the future, including making timely payments to certain vendors, landlords, lenders and similar other business partners.
• The delay in such payments may result in potential defaults under the terms of the agreements the Company has with various parties.
• The Company may not be able to access further equity or debt financing when needed.
• If additional financing is not obtained, the Company may not be able to repay its short-term obligations, which may result in a requirement to file for bankruptcy protection.

Future Outlook

The combined company will continue to operate as Neuronetics, Inc., and the Neuronetics Shares will continue to trade on the NASDAQ Global Market under the ticker STIM.

Industry Context

The acquisition reflects a trend of consolidation in the mental health services industry, where companies are seeking to expand their service offerings and geographic reach to better serve patients and compete in a rapidly evolving market.

Comparison to Industry Standards

• It is difficult to compare the results to industry standards without knowing the specific metrics used by Neuronetics and Greenbrook, and without having access to comparable data from other companies in the TMS therapy and mental health services space.
• However, some publicly traded companies in the broader healthcare services industry that could be considered for comparison include Acadia Healthcare Company, Inc. (ACHC) and Universal Health Services, Inc. (UHS), although these companies operate in different segments of the healthcare market.
• Acadia Healthcare Company, Inc. (ACHC) is a provider of behavioral healthcare services, operating a network of inpatient psychiatric facilities, residential treatment centers, and outpatient clinics.
• Universal Health Services, Inc. (UHS) is a hospital and healthcare services provider, operating acute care hospitals, behavioral health facilities, and ambulatory surgery centers.

Stakeholder Impact

• Shareholders of Greenbrook received Neuronetics shares, impacting their equity holdings.
• Employees of both companies may experience changes due to integration and restructuring.
• Patients will be impacted by the consolidation of services and the closure of some treatment centers.
• Creditors and suppliers will be affected by the financial performance of the combined entity.

Next Steps

• Finalize the acquisition accounting within one year of the acquisition date (December 9, 2025).
• Integrate Greenbrook's operations into Neuronetics.
• Implement the supplemental restructuring plan, including closing 23 treatment centers.
• Delist the Common Shares from the OTCQB Market.
• Submit an application to cease to be a reporting issuer under applicable Canadian securities laws.

Key Dates